Skip to content

BREADS: Breast Adjuvant Diet Study

IIT2018-21-Amersi-BREADS BREADS: Breast Adjuvant Diet Study

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04189263
Enrollment
6
Registered
2019-12-06
Start date
2020-02-04
Completion date
2023-03-30
Last updated
2023-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

aromatase inhibitor, carbohydrate restricted diet

Brief summary

This is a randomized controlled trial of a 6-month extreme carbohydrate restricted diet (20 grams total carbs/day) via phone counseling with dietitian plus aromatase inhibitor therapy vs. 6-month control with aromatase inhibitor therapy alone. Visits will occur at screening, 3 months, and 6 months. Anthropomorphic measurements (such as heart rate, weight, and body measurement) and questionnaires will be taken at all three visits. After screening, patients will be randomized to receive the carbohydrate restricted diet coaching immediately (Arm A) or to a control group (Arm B). Patients randomized to Arm A will receive weekly calls for the first 3 months of the intervention, then biweekly calls for the last 3 months of the intervention from the study dietitian. Total duration of the study is expected to be 3 years, though each patient's participation will be approximately 6 months.

Interventions

Carbohydrate restricted dietary intervention (\<20 g carbohydrates/day)

standard of care aromatase inhibitors

Sponsors

Farin Amersi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed breast cancer * Planning to start adjuvant hormonal therapy using an aromatase inhibitor or has started adjuvant hormonal therapy using an aromatase inhibitor * Able to read, write, and understand English * BMI ≥ 24 kg/m2 * Age ≥ 18 years * ER and/or PR positive (defined as having ≥ 1% staining for ER and/or PR on IHC) * Post-menopausal * The absence of menstrual cycles in women who have not undergone hysterectomy for at least 12 months preceding cancer diagnosis OR * History of a bilateral oophorectomy OR * History of a hysterectomy and age \>55 OR * No menses for \<1 year with FSh and estradiol levels in postmenopausal range according to institutional standards * ECOG Performance Status 0 or 1 * Female * Written informed consent obtained from subject and ability for subject to comply with requirements of the study

Exclusion criteria

* Use of hormonal therapy other than aromatase inhibitors * History of other malignancy within the past 5 years, except for malignancies with a \> 95% likelihood of cure (e.g. thyroid cancer, non-melanoma skin cancer) * Already consuming a severe carbohydrate restricted (\<20 g carbohydrates per day) diet or vegetarian diet * Currently on or plans to start chemotherapy (HER2/neu targeted therapy okay) * Medical comorbidities that in the opinion of the investigator limits the patient's ability to complete the study * Symptomatic metastases (Metastases allowed if asymptomatic) * Current use of appetite suppressant medications * Current use of any weight loss medications including herbal weight loss supplements or if patients are enrolled in a diet/weight loss program

Design outcomes

Primary

MeasureTime frameDescription
Mean change in weight6 monthsDifference in change in weight between pre- and post- intervention between carbohydrate restricted and control group

Secondary

MeasureTime frameDescription
Changes in serum estradiol6 monthsDifference in changes in serum estradiol between pre- and post-intervention between low-carbohydrate group and control group
Changes in insulin6 monthsDifference in changes in insulin between pre- and post-intervention between low-carbohydrate group and control group
Changes in HbA1c6 monthsDifference in changes in HbA1c between pre- and post-intervention between low-carbohydrate group and control group
Changes in fasting glucose6 monthsDifference in changes in fasting glucose between pre- and post-intervention between low-carbohydrate group and control group
Changes in LDL6 monthsDifference in changes in LDL between pre- and post-intervention between low-carbohydrate group and control group
Changes in HDL6 monthsDifference in changes in HDL between pre- and post-intervention between low-carbohydrate group and control group
Changes in cholesterol6 monthsDifference in changes in cholesterol between pre- and post-intervention between low-carbohydrate group and control group
Changes in triglycerides6 monthsDifference in changes in triglycerides between pre- and post-intervention between low-carbohydrate group and control group

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026